Additionally, Ranexa has significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset of 1mm ST segment depression (p=0.002), a signal of ischemia, in these Merlin-Timi 36 angina patients.
David Morrow, lead investigator of the Merlin-Timi 36 study, said: “This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina.”